Patients
primary invasive, breast cancer
Female patients with a clinical or pathologic diagnosis of stage I‐III primary invasive breast cancer were enrolled. Other key inclusion criteria were as follows: (i) ≥20 and < 70 years of age; (ii) scheduled to receive 4 cycles of neoadjuvant or adjuvant TC chemotherapy; (iii) ECOG performance status ≤2; (iv) ANC ≥1500/mm